News Focus
News Focus
icon url

YJ4LIFE

02/09/18 5:31 PM

#283366 RE: Perkin78 #283365

Yes sir I agree.

"growth across Elite's generic product lines.  Elite continued to invest heavily in product developmentwhich resulted in the positive outcome in a pilot study conducted on SequestOX™ and, in February, the filing of an ANDA for the first product being co-developed with SunGen Pharma"
icon url

AMR3

02/09/18 5:32 PM

#283367 RE: Perkin78 #283365

Agreed!
icon url

conix

02/09/18 5:36 PM

#283369 RE: Perkin78 #283365

Really? Do you know how many longs here boasted about how great their income was in 2016? When they were an R and D company?

Net Loss for first nine months of 2017

(843,758)



Profit in 2016 (first nine months)

$7,001,375


Income as a R and D company was the REASON cited by longs on why ELTP was a great investment idea.